KRYS
VENTE TOTALE: 75 000 titres (~25 866 962,50 $ US)
- Insiders
- Krishnan Suma, Krishnan Krish S, ROSSI DINO A
- Total bought
- —
- Total sold
- $25,866,962
- Last activity
- 2026-09-04
- Last synced
-
2026-09-10 10:26:50
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-15
KRYS exhibits genuinely strong financial fundamentals — clean balance sheet, high margins, and a clear profitability trajectory — which anchor the score above distressed levels.
The first sentence of the analysis written for KRYS on 2026-08-15 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 92.6% | 93.1% | 93.9% | 0.0% | 0.0% | |
| Ebit Margin | 48.7% | 35.5% | -191.8% | 0.0% | 0.0% | |
| Ebitda Margin | 50.4% | 37.8% | -180.1% | 0.0% | 0.0% | |
| Operating Profit Margin | 41.5% | 22.6% | -216.4% | 0.0% | 0.0% | |
| Pretax Profit Margin | 48.7% | 32.8% | 25.4% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 52.6% | 30.7% | 21.6% | 0.0% | 0.0% | |
| Net Profit Margin | 52.6% | 30.7% | 21.6% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 52.6% | 30.7% | 21.6% | 0.0% | 0.0% | |
| Current Ratio | 9.953 | 7.275 | 17.765 | 13.304 | 17.185 | |
| Quick Ratio | 9.560 | 7.015 | 17.554 | 13.304 | 17.185 | |
| Solvency Ratio | 1.850 | 0.876 | 0.424 | -3.771 | -2.070 | |
| Cash Ratio | 4.821 | 3.381 | 10.828 | 5.612 | 13.259 | |
| Price To Earnings Ratio | 34.822 | 50.212 | 310.150 | -14.430 | -22.348 | |
| Price To Earnings Growth Ratio | 0.274 | 0.074 | -2.891 | -0.191 | -0.269 | |
| Forward Price To Earnings Growth Ratio | 0.274 | 0.074 | -2.891 | -0.191 | -0.269 | |
| Price To Earnings Diluted Ratio | 36.044 | 52.220 | 318.103 | -14.430 | -22.348 | |
| Price To Earnings Diluted Growth Ratio | 0.282 | 0.078 | -2.970 | -0.191 | -0.269 | |
| Price To Book Ratio | 5.851 | 4.733 | 4.326 | 3.867 | 2.616 | |
| Price To Sales Ratio | 18.338 | 15.418 | 66.446 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | 37.773 | 37.583 | -33.485 | -13.152 | -13.354 | |
| Price To Operating Cash Flow Ratio | 35.526 | 36.293 | -37.934 | -20.081 | -32.389 | |
| Debt To Assets Ratio | 0.007 | 0.007 | 0.010 | 0.016 | 0.013 | |
| Debt To Equity Ratio | 0.008 | 0.008 | 0.010 | 0.017 | 0.014 | |
| Debt To Capital Ratio | 0.008 | 0.008 | 0.010 | 0.017 | 0.013 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.094 | 1.116 | 1.051 | 1.069 | 1.055 | |
| Working Capital Turnover Ratio | 0.498 | 0.486 | 0.111 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | 1.951 | 1.210 | -2.683 | -3.486 | -1.863 | |
| Operating Cash Flow Sales Ratio | 0.516 | 0.425 | -1.752 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.941 | 0.966 | 1.133 | 1.527 | 2.426 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -44.389 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -45.761 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 21.508 | 16.998 | -10.972 | -11.258 | -5.974 | |
| Capital Expenditure Coverage Ratio | 16.807 | 29.122 | -7.526 | -1.898 | -0.702 | |
| Dividend Paid And Capex Coverage Ratio | 16.807 | 29.122 | -7.526 | -1.898 | -0.702 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 33.919 | 37.682 | -33.055 | -15.979 | -18.413 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 92.6% | ▼-0.5% | ▲36.7% |
| Ebit Margin | 48.7% | ▲13.2% | ▲70.2% |
| Ebitda Margin | 50.4% | ▲12.5% | ▲68.8% |
| Operating Profit Margin | 41.4% | ▲18.8% | ▲71.9% |
| Pretax Profit Margin | 48.7% | ▲15.9% | ▲27.3% |
| Continuous Operations Profit Margin | 52.6% | ▲21.9% | ▲31.7% |
| Net Profit Margin | 52.6% | ▲21.9% | ▲31.7% |
| Bottom Line Profit Margin | 52.6% | ▲21.9% | ▲31.7% |
| Current Ratio | 9.953 | ▲2.678 | ▼-3.143 |
| Quick Ratio | 9.560 | ▲2.545 | ▼-3.364 |
| Solvency Ratio | 1.850 | ▲0.975 | ▲2.389 |
| Cash Ratio | 4.821 | ▲1.440 | ▼-2.759 |
| Price To Earnings Ratio | 34.822 | ▼-15.389 | ▼-36.859 |
| Price To Earnings Growth Ratio | 0.274 | ▲0.201 | ▲0.875 |
| Forward Price To Earnings Growth Ratio | 0.274 | ▲0.201 | ▲0.875 |
| Price To Earnings Diluted Ratio | 36.044 | ▼-16.176 | ▼-37.874 |
| Price To Earnings Diluted Growth Ratio | 0.282 | ▲0.204 | ▲0.896 |
| Price To Book Ratio | 5.851 | ▲1.118 | ▲1.573 |
| Price To Sales Ratio | 18.338 | ▲2.920 | ▼-1.702 |
| Price To Free Cash Flow Ratio | 37.773 | ▲0.190 | ▲34.700 |
| Price To Operating Cash Flow Ratio | 35.526 | ▼-0.767 | ▲39.243 |
| Debt To Assets Ratio | 0.007 | ▲0.000 | ▼-0.004 |
| Debt To Equity Ratio | 0.008 | -0.000 | ▼-0.004 |
| Debt To Capital Ratio | 0.008 | -0.000 | ▼-0.004 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.094 | ▼-0.022 | ▲0.017 |
| Working Capital Turnover Ratio | 0.498 | ▲0.012 | ▲0.279 |
| Operating Cash Flow Ratio | 1.951 | ▲0.741 | ▲2.925 |
| Operating Cash Flow Sales Ratio | 0.516 | ▲0.091 | ▲0.678 |
| Free Cash Flow Operating Cash Flow Ratio | 0.941 | ▼-0.025 | ▼-0.458 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲8.878 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲9.152 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 21.508 | ▲4.511 | ▲19.448 |
| Capital Expenditure Coverage Ratio | 16.807 | ▼-12.315 | ▲9.647 |
| Dividend Paid And Capex Coverage Ratio | 16.807 | ▼-12.315 | ▲9.647 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 33.919 | ▼-3.763 | ▲33.088 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $7.14B | $4.48B | $3.37B | $2.02B | $1.55B | |
| Enterprise value | $6.65B | $4.14B | $3.02B | $1.87B | $1.22B | |
| EV / Sales | 17.09x | 14.26x | 59.54x | 0.00x | 0.00x | |
| EV / Op. cash flow | 33.10x | 33.56x | -33.99x | -18.56x | -25.44x | |
| EV / Free cash flow | 35.20x | 34.75x | -30.00x | -12.16x | -10.49x | |
| EV / EBITDA | 33.92x | 37.68x | -33.05x | -15.98x | -18.41x | |
| Net debt / EBITDA | -2.48x | -3.07x | 3.83x | 1.31x | 5.03x | |
| Current ratio | 9.95x | 7.28x | 17.77x | 13.30x | 17.18x | |
| Income quality | 0.98x | 1.38x | -8.12x | 0.72x | 0.69x | |
| Graham number | $82 | $48 | $16 | — | — | |
| Graham net-net | $29 | $20 | $19 | $13 | $18 | |
| Tax burden | 108.1% | 93.5% | 84.8% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 92.4% | -13.3% | 116.5% | 102.2% | |
| Working capital | $921.7M | $640.0M | $554.8M | $354.9M | $416.5M | |
| Invested capital | $1.08B | $801.5M | $723.0M | $524.7M | $536.1M | |
| Return on assets | 15.4% | 8.4% | 1.3% | -25.1% | -11.1% | |
| Operating ROA | 13.5% | 7.0% | -15.9% | -24.5% | -14.6% | |
| Return on tangible assets | 15.4% | 8.4% | 1.3% | -25.1% | -11.1% | |
| Return on equity | 16.8% | 9.4% | 1.4% | -26.8% | -11.7% | |
| Return on invested capital | 13.1% | 6.4% | -11.8% | -27.3% | -11.3% | |
| Return on capital employed | 13.1% | 6.9% | -14.0% | -27.4% | -11.4% | |
| Earnings yield | 2.9% | 2.0% | 0.3% | -6.9% | -4.5% | |
| Free cash flow yield | 2.6% | 2.7% | -3.0% | -7.6% | -7.5% | |
| Capex / Op. cash flow | 5.9% | 3.4% | -13.3% | -52.7% | -142.6% | |
| Capex / Depreciation | 182.4% | 63.1% | 235.7% | 1306.5% | 2467.9% | |
| Capex / Sales | 3.1% | 1.5% | 23.3% | 0.0% | 0.0% | |
| SG&A / Sales | 37.7% | 39.1% | 194.1% | 0.0% | 0.0% | |
| R&D / Sales | 14.9% | 18.4% | 91.6% | 0.0% | 0.0% | |
| Stock comp / Sales | 14.0% | 16.9% | 78.8% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 120d | 132d | 303d | 0d | 0d | |
| Days payables outstanding | 41d | 91d | 218d | 0d | 0d | |
| Operating cycle | 633d | 614d | 1127d | 0d | 0d | |
| Cash conversion cycle | 592d | 523d | 909d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+59.3%EV / Sales ▲+19.9%EV / EBITDA ▼-10.0%EV / Op. cash flow ▼-0.456Earnings yield ▲+0.009Graham number ▲+33.719
Profitability
Return on equity ▲+0.074Return on assets ▲+0.069Return on invested capital ▲+0.067Return on capital employed ▲+0.062Operating ROA ▲+0.065Income quality ▼-0.404Tax burden ▲+0.146
Efficiency
Days sales outstanding ▼-12.078Days payables outstanding ▼-49.624Operating cycle ▲+19.067Cash conversion cycle ▲+68.691Capex / Sales ▲+0.016R&D / Sales ▼-0.035
Balance-sheet strength
Current ratio ▲+2.678Net debt / EBITDA ▲+0.587Working capital ▲+281610000.000Invested capital ▲+278177000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+359.6%EV / Sales n/aEV / EBITDA ▲+284.2%EV / Op. cash flow ▲+58.539Earnings yield ▲+0.074
Profitability
Return on equity ▲+0.285Return on assets ▲+0.265Return on invested capital ▲+0.244Return on capital employed ▲+0.245Operating ROA ▲+0.281Income quality ▲+0.292Tax burden ▲+0.081
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-7.232Net debt / EBITDA ▼-7.516Working capital ▲+505129000.000Invested capital ▲+543561000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2022-12-11 | Chris Jacobs | Purchase | $1,001 - $15,000 |
Recent news
- 2026-09-03 Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally? KRYS'' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.
- 2026-09-03 Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference PITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will take part in a fireside chat scheduled at 3:55 pm ET and host investor meetings throughout the day.
- 2026-09-02 Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue? Krystal Biotech (KRYS) reported earnings 30 days ago. What''s next for the stock?
- 2026-08-14 Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names like Wayfair, Roku, and Fox Corporation, while cooler inflation data reshuffled bets across stocks, bonds, oil, and crypto all at once.
- 2026-08-04 Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.
- 2026-08-03 Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript
- 2026-08-03 Krystal Biotech Q2 Earnings Call Highlights Krystal Biotech NASDAQ: KRYS reported second-quarter 2026 net revenue of $119.2 million from global sales of VYJUVEK, up 24% from $96 million in the prior-year period, as the company expanded treatment access for patients with dystrophic epidermolysis bullosa, or DEB, in the United States and overseas.
- 2026-08-03 Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.79 per share, beating the Zacks Consensus Estimate of $1.7 per share. This compares to earnings of $1.29 per share a year ago.
- 2026-08-03 Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results $119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year Strong balance sheet, ending the quarter with $1.1 billion in cash and investments PITTSBURGH, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company” or “Krystal”) (NASDAQ: KRYS) today reported financial results for the second quarter ended June 30, 2026 and provided a business update. “Our second quarter reflects the strength of the Krystal model: a global commercial product that continues to perform, a strong balance sheet, and a pipeline now moving toward multiple registrational readouts,” said Krish S.
- 2026-07-29 Krystal Biotech: International Expansion And A Vibrant Pipeline Krystal Biotech (KRYS) earns a STRONG BUY rating, driven by its fortress-like balance sheet, exceptional margins, and rapid Vyjuvek commercial success. KRYS''s international Vyjuvek launches in Europe and Japan are accelerating topline growth, with further expansion into Italy, Spain, and the UK expected to boost revenues. KRYS''s pipeline, leveraging its proprietary HSV-1 platform, spans respiratory, ophthalmology, oncology, and aesthetics, reducing future reliance on Vyjuvek.